Pharma Marketing Talk

Is the M&A Frenzy Short-Circuiting Pharma R&D? A Former Researcher Speaks Out

Pharmaguy

Pharmaguy

Call in to speak with the host

(347) 996-5894

A conversation with Kenneth "Eric" Milgram, Ph.D., Principal, Applied Scientific Consulting, former Director, Systems Biology Technologies at Wyeth Pharmaceuticals/Pfizer, about what happens to pharmaceutical companies when they put Wall Street expectations ahead of science-driven innovation.
Tags:
pharmaceutical
marketing
Wall Street
Research
Mergers
Broadcast in Business
h:755
s:887431
archived

Comments

 comments